Qiagen has identified Parse Biosciences’ technology as complementary to its sample technology and bioinformatic businesses.

New plate-based multiplexing unlocks ultra high-sample and cell-throughput single cell analysis to empower a broad range of studies PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ -- 10x Genomics, Inc.

New plate-based multiplexing unlocks ultra high-sample and cell-throughput single cell analysis to empower a broad range of studies With the new assay, researchers can now profile up to 384 samples ...

Eric Whitaker also is known for helping to launch General Counsels United earlier this year, in response to President Donald ...

Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

On October 29, 2025, 10x Genomics announced the launch of its next-generation Chromium Flex assay, designed to help ...

Using sophisticated RNA sequencing technology, biomedical researchers can measure the activity of our genes across millions ...

Cervical squamous cell carcinoma (CESC), the most prevalent subtype of cervical cancer, remains a major global health burden ...